Asiye YURTTAŞ

Dr. Asiye YURTTAŞ

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2023 in Joint Diseases and Related Surgery
Verified
Journal Article
Open access
OBOzan Beytemur
Ozan Beytemur
MDMustafa Fatih Dasci
Mustafa Fatih Dasci
AYAsiye YURTTAŞ
Asiye YURTTAŞ
BBBusra Yaprak Bayrak
Busra Yaprak Bayrak
EAEnder Alagöz
Ender Alagöz
Joint Diseases and Related Surgery (JDRS), the official journal of the Turkish Joint Diseases Foundation, is an international, peer-reviewed, immediate open access journal. All published articles in JDRS has been free for everyone, without embargo, since 1990.

22 June 2023 in Pathology - Research and Practice
Verified
Journal Article
Closed access
AYAsiye YURTTAŞ
Asiye YURTTAŞ
MDMustafa Fatih Dasci
Mustafa Fatih Dasci

21 October 2022 in Joint Diseases and Related Surgery
Verified
Journal Article
Open access
PDF file
MDMustafa Fatih Dasci
Mustafa Fatih Dasci
ESElif Yaprak Sarac
Elif Yaprak Sarac
AYAsiye YURTTAŞ
Asiye YURTTAŞ
TATolgahan Atci
Tolgahan Atci
MUMuhammed Uslu
Muhammed Uslu
EAEnder Alagoz
Ender Alagoz
Joint Diseases and Related Surgery (JDRS), the official journal of the Turkish Joint Diseases Foundation, is an international, peer-reviewed, immediate open access journal. All published articles in JDRS has been free for everyone, without embargo, since 1990.

18 October 2023 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
TETUĞBA ELGÜN
TUĞBA ELGÜN
AYAsiye YURTTAŞ
Asiye YURTTAŞ
KCKamil Cinar
Kamil Cinar
SOSennur Ozcelik
Sennur Ozcelik
AGAhmet Gul
Ahmet Gul

19 February 2023 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
AYAsiye YURTTAŞ
Asiye YURTTAŞ
ZOZehra Okat
Zehra Okat
TETugba Elgun
Tugba Elgun
KCKezban Ucar Ci̇fCi̇
Kezban Ucar Ci̇fCi̇
ASAltug Mert Sevim
Altug Mert Sevim
AGAhmet Gul
Ahmet Gul

1 April 2022 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
OKOnur Olgac Karagulle
Onur Olgac Karagulle
AYAsiye YURTTAŞ
Asiye YURTTAŞ
We aimed to examine the potential anticancer effects of ozone applied after chemotherapeutic treatment with different concentrations of doxorubicin in Luminal-A subtype of human breast cancer cell line (MCF-7) and compare the results with effects on L929 fibroblast cell line. Both cell lines were incubated with increasing doses of doxorubicin (1-50 μM) for 24 h at 37°C. Then, half of groups were incubated with 30 μg/mL ozone for 25 min as combination groups. Cell viability was analyzed by MTT assay, apoptosis by flow cytometry, and levels of tumor necrosis factor alpha, transforming growth factor beta, and matrix metalloproteinase-2 and MMP-9 by immunocytochemistry. Doxorubicin + ozone treatment enhanced viability of L929 (p<0.01) but reduced viability of MCF-7 compared to only doxorubicin-applied cells without ozone treatment (p<0.001). This combined treatment also enhanced apoptotic effect of doxorubicin on MCF-cells (p<0.001), but not on L929. It significantly increased all protein levels of L929 compared with those of other groups (p<0.05 for tumor necrosis factor alpha and MMP-2; p<0.01 for transforming growth factor beta and MMP-9). This treatment reversed the effect of doxorubicin on tumor necrosis factor alpha levels and considerably reduced MMP-2 and MMP-9 levels of MCF-7 compared with those of control group (p<0.01 and p<0.001, respectively). Ozone treatment potentiated the apoptotic and anticancer activities of doxorubicin in MCF-7 cells and showed repairing and healing effect on healthy fibroblast cells, which were damaged from cytotoxic effects of chemotherapeutic agent. MCF-7 cells may acquire sensitivity against the doxorubicin combined with ozone treatment through activating tumor necrosis factor alpha, MMP-2, and MMP-9 expressions.